Literature DB >> 17912759

Intra-articular electrotransfer of plasmid encoding soluble TNF receptor variants in normal and arthritic mice.

C Bloquel1, A Denys, M C Boissier, F Apparailly, P Bigey, D Scherman, N Bessis.   

Abstract

BACKGROUND: Anti-inflammatory gene therapy is promising in inflammatory diseases such as rheumatoid arthritis (RA). We have previously demonstrated that intra-muscular (i.m.) electrotransfer (ET) of plasmids encoding three different human tumor necrosis factor-alpha-soluble receptor I variants (hTNFR-Is) exert protective effects in an experimental RA model. However, such a systemic approach could be responsible for side effects. The present study aimed at performing an intra-articular (i.a.) gene therapy by electrotransfer using the hTNFR-Is plasmids. METHODS AND
RESULTS: We evaluated targeting of mice joints by CCD optical imaging after i.a. ET of a luciferase-encoding plasmid and we showed that ET led to strongly increased transgene expression in a plasmid dose-dependent manner. Moreover, articular and seric hTNFR-Is was detectable for 2 weeks. As expected, systemic hTNFR-Is rates were lower after i.a. ET than after i.m. ET. A longer protein secretion could be achieved with several i.a. ETs. Also, we observed that hTNFR-Is expression within arthritic joints was slightly higher than in normal joints.
CONCLUSIONS: In collagen-induced arthritis (CIA), a mouse model for RA, we demonstrated that hTNFR-Is/mIgG1-encoding plasmid i.a. ET decreased joint destruction in the ankles. In conclusion, our results suggest that local TNFR-Is gene therapy may play a role in decreasing joint destruction in CIA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912759     DOI: 10.1002/jgm.1088

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  6 in total

1.  Gene transfer: how can the biological barriers be overcome?

Authors:  Jean-Michel Escoffre; Justin Teissié; Marie-Pierre Rols
Journal:  J Membr Biol       Date:  2010-07-10       Impact factor: 1.843

Review 2.  Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.

Authors:  Angela M Bodles-Brakhop; Richard Heller; Ruxandra Draghia-Akli
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

3.  Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.

Authors:  John R Zibert; Katrin Wallbrecht; Margarete Schön; Lluis M Mir; Grete K Jacobsen; Veronique Trochon-Joseph; Céline Bouquet; Louise S Villadsen; Ruggero Cadossi; Lone Skov; Michael P Schön
Journal:  J Clin Invest       Date:  2010-12-06       Impact factor: 14.808

Review 4.  Evaluating intra-articular drug delivery for the treatment of osteoarthritis in a rat model.

Authors:  Kyle D Allen; Samuel B Adams; Lori A Setton
Journal:  Tissue Eng Part B Rev       Date:  2010-02       Impact factor: 6.389

Review 5.  Perspectives on the use of gene therapy for chronic joint diseases.

Authors:  Steven C Ghivizzani; Elvire Gouze; Jean-Noel Gouze; Jesse D Kay; Marsha L Bush; Rachael S Watson; Padraic P Levings; David M Nickerson; Patrick T Colahan; Paul D Robbins; Christopher H Evans
Journal:  Curr Gene Ther       Date:  2008-08       Impact factor: 4.391

6.  Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.

Authors:  Laure Delavallée; Luca Semerano; Eric Assier; Géraldine Vogel; Grégoire Vuagniaux; Marion Laborie; Daniel Zagury; Natacha Bessis; Marie-Christophe Boissier
Journal:  Arthritis Res Ther       Date:  2009-12-23       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.